Michael Zasloff

Denise Barbut

Mark Finn

Richard D. Propper

Jay Brammer

Michael Zasloff, MD, PhD

Founder, Chairman and CSO

Professor of Pediatrics and Genetics, Georgetown University, Dean of Research and Translational Science at Georgetown University, founder of Magainin and former President Magainin Research Institute

Over the past 25 years, Dr. Zasloff’s scientific interests have centered on the innate immune systems of animals. Dr. Zasloff received his M.D.-Ph.D. in the Medical Scientist Training Program at New York University School of Medicine. In the 1980’s, Dr. Zasloff was Chief, Human Genetics Branch, National Institutes of Child Health and Human Development, at the National Institutes of Health. In 1988 Dr Zasloff founded Magainin Pharmaceuticals, Inc. a publicly traded biotechnology company. In the same year he joined the faculty of the University of Pennsylvania School of Medicine as the Charles E. H. Upham Professor of Pediatrics and Genetics, and assumed the position of Director of the Division of Human Genetics of the Children’s Hospital of Philadelphia.  In July 1992 Dr. Zasloff left Penn and joined Magainin on a full time basis, and served as Executive Vice President and President of the Magainin Research Institute, a basic research division of the Company. From July 1996 through November 2000 Dr. Zasloff was Vice Chairman of the Board of Magainin Pharmaceuticals.  In 2002, Dr. Zasloff was named Dean of Research and Translational Science at Georgetown, tasked with the integration of the basic science conducted at Georgetown with the clinical environment of the Medical Center. Between 2004 and 2006 Dr. Zasloff also served as Senior Vice President for Biotechnology for Ferris, Baker Watts, and an investment firm in D.C.

Since 2004, Dr. Zasloff has been actively engaged in studies of innate immunity as Scientific Director of the MedStar-Georgetown Transplant Institute.  His research interests remain focused on the role of antimicrobial peptides and aminosterols in health and disease, and application to the prevention and treatment of disease. He has published over 150 peer reviewed articles, and holds over 40 issued US patents.

He founded Enterin in 2016 and serves as Chairman and CSO. He also serves as the lead independent Director on the Board of Amphastar Pharmaceuticals, Inc. and is a Director at Sarentis Therapeutics and Novo Therapeutics. He has received numerous awards including an honorary Doctor of Science from Georgetown University in 2011.

Denise Barbut, MD, FRCP

Co-founder, President and Chief Medical Officer

Professor of Neurology & Former Chief of Neurovascular Division at Weill-Cornell Medical College. Founder, Chair, and CEO of several med-tech and biotech companies. Holder of close to 200 patents.

Dr. Barbut was brought up in Istanbul, Turkey. She trained as an internist and subsequently as a neurologist in Great Britain and the USA. She received her bachelor’s degree from University College London and her Medical Degree from University College Hospital. She did her post-graduate training at Imperial College, the Royal Brompton Hospital and the National Hospital for Neurology and Neurosurgery, Queens’ Square. She is a Fellow of the Royal College of Physicians of the United Kingdom. She completed her neurologic training at Weill-Cornell Medical Center- Cornell University Medical College and Memorial Sloan-Kettering Cancer Center. Subsequently she became an Attending Physician at New York Hospital and Professor of Neurology at Cornell University. She was Chief of the Neurovascular Division and of the Stroke Research Program.

She left academia in 2000 after founding the second of her 5 companies. Dr. Barbut is sole author or lead author on close to 200 issued or pending patents, mostly relating to methods for neuroprotection, cerebral hypothermia, the treatment of cerebral ischemia, pain, neuromodulation, Parkinson’s disease and other neurodegenerative disorders. She is also the lead or senior author on over 100 peer-reviewed articles and abstracts. She has been involved in founding, funding and running biotech companies for 20 years.

She recently co-founded Enterin, where she serves as President and CMO. She is also Board Chair at Novo Therapeutics, Sarentis Therapeutics and Muse and Board member at Israel Brain Technologies.

Mark Finn

Mark Finn has 49 years of investment experience. In 1975, Mark joined the predecessor to the Vantage Consulting Group as an outside consultant and was elected its Chairman and Chief Executive Officer in 1986, a capacity in which he continues to serve today. Since 1990, Mr. Finn has also served as an Independent Trustee on a number of independent open end funds sponsored by Legg Mason (previously CitiFunds).

Mr. Finn currently serves on the Board and Chairs the Finance Committee of Cibus Global, a leading agricultural biotechnology firm focused on advanced non-transgenic trait development. He also serves on the Advisory Board of Auven Therapeutics, a private equity life sciences company with an emphasis on cancer. He joined the Board of Directors at Enterin Inc. in 2017.

He has taught investments at the University of Virginia’s Colgate Darden Graduate Business School and is currently on the adjunct faculty at the Mason School of Business at the College of William & Mary, where he received his MBA. Mr. Finn also serves as the Managing Member of New Ventures I, LLC, New Ventures Select, LLC and New Ventures III.

Richard D. Propper, MD

Dr. Propper is an experienced venture capitalist, merchant banker and financial strategist. He received a BSc from McGill University and a MD from Stanford University. Dr. Propper worked as a Research Fellow in Pediatrics at Harvard Medical School. He was also a Fellow in Medicine at the Children’s Hospital Medical Center, Fellow in Pediatric Oncology at the Dana Farber Cancer Center, and Assistant Professor in Pediatrics at Harvard Medical School. He has published over 40 papers and three textbook chapters, and is renowned for his clinical research in thalassemia major.

In 1984, Dr. Propper found Montgomery Medical Ventures, the largest seed-stage medical venture capital firm in the country at that time, with $135M in capital. In 1993, he founded the International Medical Development Corporation to pursue healthcare ventures worldwide. In 1998, he co-founded Medibuy.com., the largest Internet-based medical procurement company in the US. In 2001, Dr. Propper founded Chardan Ventures, the predecessor to Chardan Capital, LLC, a financial strategic consulting firm building business between Chinese and US companies

In 2003, he raised his first SPAC, Chardan China Acquisition Corporation, which eventually merged with Origin Agritech, and is currently a NASDAQ-listed company (SEED). In 2005, he raised two more SPACs, one of which became NASDAQ-listed HollySys (HOLI).

Dr. Propper currently serves on the Boards of FreeLinc Technologies, Inc. and HyEdge, Inc. He joined the Board of Directors at Enterin Inc. in 2016.

Jay Brammer

CEO and Board Member

Jay Brammer is the CEO and a Board Member of Enterin. During his 40 year business career, Mr. Brammer has been an executive, board member and/or investor across numerous companies in various industries. Concurrently, Mr. Brammer serves as Chairman & Chief Investment Officer at Indie Asset Partners, an investment advisory firm providing alternative investment options to private clients. Prior to co-founding Indie Asset Partners, Mr. Brammer established a number of mutual funds and successfully managed multiple real estate businesses. Mr. Brammer graduated with a degree in business administration from the Indiana University.